Show simple item record

dc.contributor.authorTabrizi, SN
dc.contributor.authorTan, LY
dc.contributor.authorWalker, S
dc.contributor.authorTwin, J
dc.contributor.authorPoljak, M
dc.contributor.authorBradshaw, CS
dc.contributor.authorFairley, CK
dc.contributor.authorBissessor, M
dc.contributor.authorMokany, E
dc.contributor.authorTodd, AV
dc.contributor.authorGarland, SM
dc.date.accessioned2021-02-04T01:19:05Z
dc.date.available2021-02-04T01:19:05Z
dc.date.issued2016-06-06
dc.identifierpii: PONE-D-16-14821
dc.identifier.citationTabrizi, S. N., Tan, L. Y., Walker, S., Twin, J., Poljak, M., Bradshaw, C. S., Fairley, C. K., Bissessor, M., Mokany, E., Todd, A. V. & Garland, S. M. (2016). Multiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology. PLOS ONE, 11 (6), https://doi.org/10.1371/journal.pone.0156740.
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11343/259323
dc.description.abstractMycoplasma genitalium is a cause of non-gonoccocal urethritis (NGU) in men and cervicitis and pelvic inflammatory disease in women. Recent international data also indicated that the first line treatment, 1 gram stat azithromycin therapy, for M. genitalium is becoming less effective, with the corresponding emergence of macrolide resistant strains. Increasing failure rates of azithromycin for M. genitalium has significant implications for the presumptive treatment of NGU and international clinical treatment guidelines. Assays able to predict macrolide resistance along with detection of M. genitalium will be useful to enable appropriate selection of antimicrobials to which the organism is susceptible and facilitate high levels of rapid cure. One such assay recently developed is the MG 23S assay, which employs novel PlexZyme™ and PlexPrime™ technology. It is a multiplex assay for detection of M. genitalium and 5 mutations associated with macrolide resistance. The assay was evaluated in 400 samples from 254 (186 males and 68 females) consecutively infected participants, undergoing tests of cure. Using the MG 23S assay, 83% (331/440) of samples were positive, with 56% of positives carrying a macrolide resistance mutation. Comparison of the MG 23S assay to a reference qPCR method for M. genitalium detection and high resolution melt analysis (HRMA) and sequencing for detection of macrolide resistance mutations, resulted in a sensitivity and specificity for M. genitalium detection and for macrolide resistance of 99.1/98.5% and 97.4/100%, respectively. The MG 23S assay provides a considerable advantage in clinical settings through combined diagnosis and detection of macrolide resistance.
dc.languageEnglish
dc.publisherPUBLIC LIBRARY SCIENCE
dc.titleMultiplex Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance Using PlexZyme and PlexPrime Technology
dc.typeJournal Article
dc.identifier.doi10.1371/journal.pone.0156740
melbourne.affiliation.departmentUniversity General
melbourne.affiliation.departmentObstetrics and Gynaecology
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.affiliation.department
melbourne.affiliation.facultyUniversity Services
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titlePLoS One
melbourne.source.volume11
melbourne.source.issue6
dc.rights.licenseCC BY
melbourne.elementsid1066867
melbourne.contributor.authorTabrizi, Sepehr
melbourne.contributor.authorBradshaw, Catriona
melbourne.contributor.authorFairley, Christopher
melbourne.contributor.authorWark, Suzanne
melbourne.contributor.authorPOLJAK, MARIN
dc.identifier.eissn1932-6203
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record